The European Commission has granted a marketing authorization for Aerie Pharmaceuticals (NASDAQ:AERI) Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension.
The marketing authorization application is expected by early 2020 and company expects that review process would take approximately one year.
The marketing authorization is valid in all 28 countries of the European Union, plus Iceland, Norway and Liechtenstein.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.